[Pharmacokinetic studies on aztreonam in late pregnancy in sheep and humans].
The transplacental passage of single intravenous doses of aztreonam (AZT), 1 g or 2 g, was examined in 7 sheep and 14 women in late pregnancy, respectively and the obtained data were analyzed by a two-compartment model. The obtained results were summarized as follows. After single 2 g intravenous doses were given to pregnant sheep, the mean peak level of AZT in maternal blood was 83.79 micrograms/ml and the half-life of the beta-phase was 1.525 hours. After single 1 g intravenous doses were administered to pregnant women, the mean peak level of AZT in blood was 102.62 micrograms/ml and the half-life of beta-phase was 2.128 hours. The peak levels in umbilical venous blood and amniotic fluid were 14.43 micrograms/ml and 11.86 micrograms/ml, respectively.
D000653:Amniotic Fluid / Q000378:metabolism; D000818:Animals; D001398:Aztreonam / Q000378:metabolism*; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008431:Maternal-Fetal Exchange; D011247:Pregnancy / Q000378:metabolism*; D011263:Pregnancy Trimester, Third; D011270:Pregnancy, Animal / Q000378:metabolism*; D012756:Sheep
D001398:Aztreonam